Total Funding
54
Total FundingDebt Financing raised
Growth Score
pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
AngioChem develops new drugs that are capable of crossing the blood-brain barrier to treat brain diseases.
About the Company
AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered
Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.
